Literature DB >> 3076128

Perspectives in corticosteroid research.

M Töpert1.   

Abstract

In dermatotherapy, potent drugs are needed which can be used as alternatives to corticosteroids, but which are without unwanted local and systemic effects. Three theoretical possibilities for the development of such advanced drugs have been presented. Firstly, dissociation of wanted and unwanted effects by selection of a certain corticosteroid structure is proposed. However, this is impossible, because corticosteroid receptors are ubiquitous and all display the same specificity. Secondly, manipulation of the pathways of the inflammatory response may be more feasible. Because of increasing knowledge of the mechanism of inflammation and the pathogenesis of cutaneous inflammatory diseases, it is predictable that effective nonsteroidal anti-inflammatory drugs for topical use will be developed some time in the future. Lastly, the effects and side effects can now be limited to the site of application, thus avoiding systemic risks, by optimising corticosteroid activity with respect to receptor binding and pharmacokinetic properties. However, it is realistic to assume that, even in the future, corticosteroids will always possess both desirable and undesirable properties.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3076128     DOI: 10.2165/00003495-198800365-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  13 in total

1.  Multiple control of inflammation by glucocorticoids.

Authors:  M Di Rosa; A Calignano; R Carnuccio; A Ialenti; L Sautebin
Journal:  Agents Actions       Date:  1986-01

2.  Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity.

Authors:  B P Wallner; R J Mattaliano; C Hession; R L Cate; R Tizard; L K Sinclair; C Foeller; E P Chow; J L Browing; K L Ramachandran
Journal:  Nature       Date:  1986 Mar 6-12       Impact factor: 49.962

3.  Background and discovery of lipocortins.

Authors:  R J Flower
Journal:  Agents Actions       Date:  1986-01

4.  [Pharmacological studies on butyl 6alpha-fluoro-11beta-hydroxy-16alpha-methyl-3,20-dioxo-1,4-pregnadien-21-oate (fluocortin butylester) (author's transl)].

Authors:  J F Kapp; H Koch; M Töpert; H J Kessler; E Gerhards
Journal:  Arzneimittelforschung       Date:  1977

Review 5.  Physiological functions of glucocorticoids in stress and their relation to pharmacological actions.

Authors:  A Munck; P M Guyre; N J Holbrook
Journal:  Endocr Rev       Date:  1984       Impact factor: 19.871

6.  Leukotrienes as mediators of skin inflammation.

Authors:  A W Ford-Hutchinson; A Rackman
Journal:  Br J Dermatol       Date:  1983-07       Impact factor: 9.302

7.  The role of transcortin in glucocorticoid mediated enzyme induction: tyrosine aminotransferase induction in hepatoma tissue culture cells.

Authors:  M Lippman; E B Thompson
Journal:  J Steroid Biochem       Date:  1974-08       Impact factor: 4.292

8.  Corticosteroid atrophy in human skin. A study by light, scanning, and transmission electron microscopy.

Authors:  P Lehmann; P Zheng; R M Lavker; A M Kligman
Journal:  J Invest Dermatol       Date:  1983-08       Impact factor: 8.551

9.  Production of intraepidermal microabscesses by topical application of leukotriene B4.

Authors:  R Camp; R R Jones; S Brain; P Woollard; M Greaves
Journal:  J Invest Dermatol       Date:  1984-02       Impact factor: 8.551

10.  Leukotriene biosynthesis inhibitors.

Authors:  J R Cashman
Journal:  Pharm Res       Date:  1985-11       Impact factor: 4.200

View more
  4 in total

Review 1.  Topical corticosteroids. Which drug and when?

Authors:  B Giannotti; N Pimpinelli
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

2.  0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream.

Authors:  H C Korting; D Vieluf; M Kerscher
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Liposome encapsulation improves efficacy of betamethasone dipropionate in atopic eczema but not in psoriasis vulgaris.

Authors:  H C Korting; H Zienicke; M Schäfer-Korting; O Braun-Falco
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  BOL-303242-X, a novel selective glucocorticoid receptor agonist, with full anti-inflammatory properties in human ocular cells.

Authors:  Jin-Zhong Zhang; Megan E Cavet; Karl R VanderMeid; Mercedes Salvador-Silva; Francisco J López; Keith W Ward
Journal:  Mol Vis       Date:  2009-12-08       Impact factor: 2.367

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.